Početna › Neuroblastom › Kalifornija
Kliničke studije za Neuroblastom u državi Kalifornija
14 studija za Neuroblastom traži sudionike na lokacijama u državi Kalifornija.
Gradovi u državi Kalifornija
- San Francisco7 studija
- Los Angeles7 studija
- Mountain View5 studija
- Oakland5 studija
- San Diego5 studija
- Orange3 studija
Službeni tekst studije (engleski)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Kaiser Permanente Downey Medical Center, Downey
- City of Hope Comprehensive Cancer Center, Duarte
- Loma Linda University Medical Center, Loma Linda
- i još 13
U tijeku regrutacijaFaza 3
Do 30 godina · Oba spola · Ažurirano 2. lis 2026. · NCT06172296MCT for the Harvard/UCSF ROBIN Center
- University of California, San Francisco, San Francisco
U tijeku regrutacija
Sve dobne skupine · Oba spola · Ažurirano 1. lis 2026. · NCT06000787Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Los Angeles ( Site 1006), Los Angeles
U tijeku regrutacijaFaza 1/2
6 Months – 25 Years · Oba spola · Ažurirano 17. ruj 2026. · NCT06395103Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
U tijeku regrutacijaFaza 2
Do 22 godina · Oba spola · Ažurirano 4. ruj 2026. · NCT02559778Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
U tijeku regrutacijaFaza 1/2
Do 30 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT06541262Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Kaiser Permanente Downey Medical Center, Downey
- Loma Linda University Medical Center, Loma Linda
- Children's Hospital Los Angeles, Los Angeles
- i još 9
U tijeku regrutacijaFaza 3
365 Days – 30 Years · Oba spola · Ažurirano 25. kol 2026. · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital of Orange County, Orange
- UCSF Medical Center-Mission Bay, San Francisco
U tijeku regrutacijaFaza 1/2
12 Months – 30 Years · Oba spola · Ažurirano 25. kol 2026. · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
U tijeku regrutacijaFaza 2
12 Months – 21 Years · Oba spola · Ažurirano 12. kol 2026. · NCT05489887SPEARHEAD-3 Pediatric Study
- Stanford University, Palo Alto
U tijeku regrutacijaFaza 1/2
Od 2 do 21 godina · Oba spola · Ažurirano 11. kol 2026. · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Cedars-Sinai Medical Center, Los Angeles
- University of California, San Francisco, San Francisco
U tijeku regrutacijaFaza 1/2
Od 1 do 30 godina · Oba spola · Ažurirano 22. srp 2026. · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Children's Hospital Los Angeles, Los Angeles
- UCSF Benioff Children's Hospital, San Francisco
U tijeku regrutacijaFaza 2
Od 1 do 31 godina · Oba spola · Ažurirano 20. srp 2026. · NCT06450041Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Lucille Packard Children's Hospital Stanford, Palo Alto
U tijeku regrutacijaFaza 1/2
12 Months – 30 Years · Oba spola · Ažurirano 19. svi 2026. · NCT04901702Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
- Stanford University, Palo Alto
U tijeku regrutacijaFaza 1
Od 2 do 30 godina · Oba spola · Ažurirano 7. svi 2026. · NCT06500819Neuroblastoma Biology Study
- Children's Hospital Los Angeles, Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
U tijeku regrutacijaOpažajna studija
31 Days – 99 Years · Oba spola · Ažurirano 23. ožu 2026. · NCT01587300Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.